Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05251181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

StatusNot Yet Recruiting
PhasePhase 3
Started2026-02
View on ClinicalTrials.gov ↗
This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest. Shock is a life-threatening condition of circulatory failure. It is a state of cellular and tissue hypoxia due to reduced oxygen delivery and/or increased oxygen consumption or inadequate oxygen utilization. Shock most commonly occurs when there is circulatory failure leading to reduced tissue perfusion. There are four types of shock: distributive, cardiogenic, hypovolemic, and obstructive. However, these are not exclusive, and many patients with circulatory failure have a combination of more than one form of shock (multifactorial shock).

Amendment record

Amended 8 times since 2022-02-11; most recent filed 2025-12-26. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-12-26
Amendment Study Status v8
2025-07-01
Amendment Study Status, Contacts/Locations, References v7
2023-06-19
Amendment Study Status v6
2023-01-11
Amendment Study Status v5
2022-10-12
Amendment Study Status v4
2022-07-15
Amendment Study Status v3
2022-04-18
Amendment Study Status v2
2022-02-21
Amendment Study Identification, Study Status, Study Description, Outcome Measures v1
2022-02-11
Original filing
Trial Details
NCT Number NCT05251181
Lead Sponsor Pharmazz, Inc.
Conditions Hypovolemic Shock
Enrollment 430 participants
Start Date 2026-02
Primary Completion 2026-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-30